Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

About this update from Relmada Therapeutics, Inc.

CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: A replay of the webcast will be available in the Investors section of the Relmada website at  https://www.relmada.com/investors/ir-calendar . About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations. Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational product for compulsion-related disorders including Tourette’s Syndrome and Prader-Willi Syndrome, into further studies. For more information, visit  www.relmada.com . Follow us on LinkedIn. Investor Contact: Brian Ritchie LifeSci Advisors [email protected] Media Inquiries: Corporate Communications [email protected]

View stock analysis, news, and events for Relmada Therapeutics, Inc.